Newamsterdam Pharma Co. NV-27NAMSWPreferred / convertible
13F holders, Q3 2024 (September 30)11holders +1
1new positions
0sold out
$7.00avg. 13F price*
At the end of Q3 2024, 11 institutions reported holding Newamsterdam Pharma Co. NV-27 (NAMSW) in their 13F filings, up 1 from Q2 2024. 1 opened new positions and 0 sold out. The largest holders were Frazier Life Sciences Management, L.P. ($3.5M), Ra Capital Management, L.P. ($2.3M) and Affinity Asset Advisors, LLC ($1.5M).
- Company
- Newamsterdam Pharma Co. NV-27
- CUSIP
- N62509117
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $218K |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 41,564 shares bought and 7,020 shares sold, net +34,544 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Frazier Life Sciences Management, L.P. | — | No change | 500,333 | $3.5M |
| Ra Capital Management, L.P. | — | No change | 333,333 | $2.3M |
| Affinity Asset Advisors, LLC | — | Add +5.1% | 212,974 | $1.5M |
| Bain Capital Life Sciences Investors, LLC | — | No change | 100,000 | $700K |
| Deerfield Management Company, L.P. | — | No change | 92,787 | $650K |
| Monashee Investment Management LLC | — | New | 31,189 | $218K |
| HRT Financial LP | — | Reduce -10.6% | 27,120 | $189K |
| Laurion Capital Management LP | — | No change | 16,666 | $117K |
| Vestcor Inc | — | No change | 9,632 | $67K |
| TFC Financial Management, Inc. | — | Reduce -38.2% | 6,181 | $43K |
| CIBC Private Wealth Group LLC | — | No change | 1,000 | $7K |
"% of holder's portfolio" is NAMSW's weight in each manager's 13F, not the share of Newamsterdam Pharma Co. NV-27 the manager owns.